Select country set
language
Menu Shopping cart 0,00 Search
Manufactured by BioVendor

hsa-miR-379-5p miREIA

  • Regulatory status:RUO
  • Type:miREIA – miRNA enzyme immunoassay
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


Clearance sale RDM0046H 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

miREIA – miRNA enzyme immunoassay

Applications

Tissue extract

Sample Requirements

10 µl/well

Shipping

At ambient temperature. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the complete kit at 2 – 8 °C. Under these conditions, all components are stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

6.25 – 0.195 amol/μl

Limit of Detection

0.065 amol/μl

Intra-assay (Within-Run)

n = 8,
CV = 4.3%

Inter-assay (Run-to-Run)

n = 5,
CV = 8.6%

Spiking Recovery

100.9%

Dilution Linearity

95.5%

Specificity

Crossreactivity with the miRNA family members exhibiting high sequence identity cannot be excluded.

Note

Product Manual: miREIA - microRNA enzyme immunoassay

Have you bought miREIA kits and need help with assay procedure? Please look at product manual video how easy using the miREIA method is.


Product Manual: miREIA - microRNA enzyme immunoassay

 

Summary

Features

  • It is intended for research use only
  • The total assay time is less than 2.5 hours
  • The kit measures hsa-miR-379-5p isolated from human blood
  • Assay format is 96 wells
  • Standard is synthetic miRNA-based
  • Components of the kit are provided ready to use, concentrated or dried

Research topic

Oncology

Summary

MicroRNAs (miRNAs) are small non-coding RNA molecules, approximately 22 nucleotides in length that regulate gene translation through silencing or degradation of target mRNAs. They are involved in multiple biological processes, including differentiation and proliferation, metabolism, hemostasis, apoptosis or inflammation, and in the pathophysiology of many diseases. Numerous studies have suggested circulating miRNAs as promising diagnostic and prognostic biomarkers of many diseases.

miR-379-5p plays important roles in the pathogenesis of human cancers, including hepatocellular carcinoma (HCC), osteosarcoma (OS), glioblastoma, nasopharyngeal carcinoma, lung cancer, breast cancer and bladder cancer.

miR-379-5p, which is down-regulated in HCC tissues and cell lines, is associated with advanced TNM stage and metastasis in HCC. The ectopic overexpression of miR-379-5p inhibited HCC cell migration, invasion, epithelial-to-mesenchymal transition (EMT) and metastasis. Moreover, miR-379-5p exerted this function by directly targeting focal adhesion kinase (FAK) 3'-UTR and repressing FAK expression, thus leading to suppression of AKT signaling. In clinical samples of HCC, miR-379-5p negatively correlated with FAK, which was up-regulated in HCC.

circRNA signal-induced proliferation-associated 1 like 1 (circ_SIPA1L1) accelerated the proliferation and metastasis abilities of OS cells. MiR-379-5p directly bound to circ_SIPA1L1 and MAP3K9. MiR-379-5p interference rescued the abilities of proliferation and metastasis in OS cells, which were suppressed by the silencing of circ_SIPA1L1.

miR-379-5p were shown to participate in the development of autoimmune inflammatory processes in multiple sclerosis (MS). The upregulation of miR-126-3p, miR-146b-5p, miR-155, miR-196a-5p, miR-21-5p, miR-223-3p, miR-326 and miR-379-5p in remission compared to relapse was observed. Two of these miRNAs (miR-223-3p and miR-379-5p) were upregulated only in men.

Summary References (10)

References to miR-379-5p

  • Baulina N, Kulakova O, Kiselev I, Osmak G, Popova E, Boyko A, Favorova O. Immune-related miRNA expression patterns in peripheral blood mononuclear cells differ in multiple sclerosis relapse and remission. J Neuroimmunol. 2018 Apr 15;317:67-76. doi: 10.1016/j.jneuroim.2018.01.005. Epub 2018 Jan 5. PMID: 29325906. See more on PubMed
  • He Q, Fang Y, Lu F, Pan J, Wang L, Gong W, Fei F, Cui J, Zhong J, Hu R, Liang M, Fang L, Wang H, Yu M, Zhang ZF. Analysis of differential expression profile of miRNA in peripheral blood of patients with lung cancer. J Clin Lab Anal. 2019 Nov;33(9):e23003. doi: 10.1002/jcla.23003. Epub 2019 Sep 20. PMID: 31541491; PMCID: PMC6868404. See more on PubMed
  • Chen JS, Li HS, Huang JQ, Dong SH, Huang ZJ, Yi W, Zhan GF, Feng JT, Sun JC, Huang XH. MicroRNA-379-5p inhibits tumor invasion and metastasis by targeting FAK/AKT signaling in hepatocellular carcinoma. Cancer Lett. 2016 May 28;375(1):73-83. doi: 10.1016/j.canlet.2016.02.043. Epub 2016 Mar 2. PMID: 26944318. See more on PubMed
  • Ji W, Diao YL, Qiu YR, Ge J, Cao XC, Yu Y. LINC00665 promotes breast cancer progression through regulation of the miR-379-5p/LIN28B axis. Cell Death Dis. 2020 Jan 6;11(1):16. doi: 10.1038/s41419-019-2213-x. PMID: 31907362; PMCID: PMC6944690. See more on PubMed
  • Jun L, Xuhong L, Hui L. Circ_SIPA1L1 Promotes Osteosarcoma Progression Via miR-379-5p/MAP3K9 Axis. Cancer Biother Radiopharm. 2020 Sep 4. doi: 10.1089/cbr.2020.3891. Epub ahead of print. PMID: 32897735. See more on PubMed
  • Lv X, Wang M, Qiang J, Guo S. Circular RNA circ-PITX1 promotes the progression of glioblastoma by acting as a competing endogenous RNA to regulate miR-379-5p/MAP3K2 axis. Eur J Pharmacol. 2019 Nov 15;863:172643. doi: 10.1016/j.ejphar.2019.172643. Epub 2019 Sep 4. PMID: 31493405. See more on PubMed
  • Maemura K, Watanabe K, Ando T, Hiyama N, Sakatani T, Amano Y, Kage H, Nakajima J, Yatomi Y, Nagase T, Takai D. Altered editing level of microRNAs is a potential biomarker in lung adenocarcinoma. Cancer Sci. 2018 Oct;109(10):3326-3335. doi: 10.1111/cas.13742. Epub 2018 Sep 6. PMID: 30022565; PMCID: PMC6172074. See more on PubMed
  • Wu D, Niu X, Tao J, Li P, Lu Q, Xu A, Chen W, Wang Z. MicroRNA-379-5p plays a tumor-suppressive role in human bladder cancer growth and metastasis by directly targeting MDM2. Oncol Rep. 2017 Jun;37(6):3502-3508. doi: 10.3892/or.2017.5607. Epub 2017 Apr 27. PMID: 28498468. See more on PubMed
  • Xu X, Wang Y, Mojumdar K, Zhou Z, Jeong KJ, Mangala LS, Yu S, Tsang YH, Rodriguez-Aguayo C, Lu Y, Lopez-Berestein G, Sood AK, Mills GB, Liang H. A-to-I- edited miRNA-379-5p inhibits cancer cell proliferation through CD97-induced apoptosis. J Clin Invest. 2019 Dec 2;129(12):5343-5356. doi: 10.1172/JCI123396. PMID: 31682236; PMCID: PMC6877318. See more on PubMed
  • Zhang F, Duan C, Yin S, Tian Y. MicroRNA-379-5p/YBX1 Axis Regulates Cellular EMT to Suppress Migration and Invasion of Nasopharyngeal Carcinoma Cells. Cancer Manag Res. 2020 Jun 9;12:4335-4346. doi: 10.2147/CMAR.S253504. PMID: 32606929; PMCID: PMC7293412. See more on PubMed
Related Products Docs